Bringing the Oncology Community Together

Web Exclusives

Talimogene laherparepvec significantly improved durable response rates but failed to extend overall survival in patients with advanced melanoma.
The FDA has approved ofatumumab plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia who are considered inappropriate for treatment with fludarabine therapy.
Patients with localized prostate cancer at intermediate or high risk for progression experience better outcomes when 6 months of androgen deprivation therapy is added to standard radiotherapy.
A novel 100-locus DNA signature obtained from pretreatment biopsies accurately classified 75% of patients with untreated prostate cancer as low- or high-risk.
An updated guideline from ASCO regarding the use of sentinel lymph node (SLN) biopsy in early stage breast cancer supports the use of the procedure over axillary lymph node dissection (ALND) in a larger group of patients than previously recommended.
Five early-phase clinical trials exploring chimeric antigen receptor (CAR) T-cell therapy have been suspended temporarily in response to the deaths of 2 patients with adult B-cell acute lymphoblastic leukemia
An interview with Padmanee Sharma, MD, PhD, on the evolving field of immunotherapy for patients with castration-resistant prostate cancer.
The large phase III MAGRIT study investigating the MAGE-A3-specific vaccine GSK1572932A for patients with non-small cell lung cancer (NSCLC) will be completely halted following an interim analysis that demonstrated a lack of benefit.
Most Popular Right Now
Publications
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.